Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 319 followers
Latest posts
Last updated about 9 hours ago
Reminder: Invitation to Roche’s Pharma Day 2024
about 9 hours ago
The Roche Investor Relations team would like to invite you to the...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
about 12 hours ago
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza...
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
4 days ago
OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without...
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
7 days ago
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options...
Reminder: Invitation to Roche’s Virtual Investor Event at EASD
13 days ago
We are pleased to invite investors and analysts to participate in our...
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
15 days ago
New Phase II data show vast majority of patients experiencing no relapses...
Invitation to Roche’s Pharma Day 2024
20 days ago
The Roche Investor Relations team would like to invite you to the...
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
24 days ago
With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce...
Invitation to Roche’s Virtual Investor Event at EASD
27 days ago
We are pleased to invite investors and analysts to participate in our...
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)
about 2 months ago
Approval is based on data from two Phase III studies in branch...
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
about 2 months ago
The acquisition of LumiraDx’s Point of Care technology received all required antitrust...
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
about 2 months ago
Group sales were up by 5%1 at constant exchange rates (CER) (stable...